Analyst Price Target is $8.15
▲ +207.45% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Kinnate Biopharma in the last 3 months. The average price target is $8.15, with a high forecast of $24.00 and a low forecast of $2.00. The average price target represents a 207.45% upside from the last price of $2.65.
Current Consensus is
Hold
The current consensus among 5 polled investment analysts is to hold stock in Kinnate Biopharma. This Hold consensus rating has held steady for over two years.
Kinnate Biopharma Inc., a clinical-stage oncology company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; KIN-3248 small-molecule kinase inhibitors that target cancer-associated alterations in fibroblast growth factor receptors FGFR2 and FGFR3 genes; and small molecule research programs, including Cyclin-Dependent Kinase 12(CDK12) inhibitor in its KIN004 program. The company was incorporated in 2018 and is headquartered in San Francisco, California. Kinnate Biopharma Inc. is a former subsidiary of Fount Therapeutics, LLC.
Read More